Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
Issue Date
2009-04MeSH
Dopamine AgonistsEchocardiography
Ergolines
Heart Valve Diseases
Heart Valves
Humans
Hyperprolactinemia
Parkinson Disease
Pergolide
Tricuspid Valve Insufficiency
Metadata
Show full item recordCitation
Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. 2009, 95 (7):522-3 HeartPublisher
Heart (British Cardiac Society)Journal
Heart (British Cardiac Society)DOI
10.1136/hrt.2008.163345PubMed ID
19174419Item Type
ArticleLanguage
enISSN
1468-201Xae974a485f413a2113503eed53cd6c53
10.1136/hrt.2008.163345
Scopus Count
Collections
Related articles
- Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
- Authors: Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E
- Issue date: 2007 May
- Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
- Authors: Pullan PT
- Issue date: 2009 Apr
- Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
- Authors: Antonini A, Poewe W
- Issue date: 2007 Sep
- Dopamine agonists and hyperprolactinaemia.
- Authors: Martin NM, Tan T, Meeran K
- Issue date: 2009 Mar 3
- [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
- Authors: Steffensen C, Mægbæk ML, Laurberg P, Andersen M, Kistorp C, Nørrelund H, Dal J, Jørgensen JO
- Issue date: 2014 Jan 6